SQUAWK/NEWS
Account
Theme
Account
Menu
Live News EQUITY FLASH L impact

RBC Raises Ligand Pharmaceuticals Price Target to $357 From $345

RBC Capital Markets maintained its Outperform rating. The update followed Ligand's third-quarter 2026 results and increase to its 2026 adjusted EPS guidance.

LGND

Related stories